Kepler Cheuvreux upgrades Demant stock to buy on growth prospects

Kepler Cheuvreux upgraded Demant A/S stock to Buy from Hold, raising the price target to DKK315 from DKK240, citing an expected new hearing aid launch in summer 2025 driving growth in Q4 and into 2026. Analysts also highlighted Demant's strategic shift in managed care and pricing flexibility, viewing management's approach as pragmatic despite recent estimate cuts. The upgrade reflects confidence in Demant's ability to capitalize on opportunities, noting the stock's mid-teens discount to its historical P/E ratio suggesting potential for re-rating.

Analysis

Kepler Cheuvreux has upgraded Demant A/S stock to Buy from Hold, increasing the price target significantly to DKK315 from DKK240. This improved outlook is primarily driven by the anticipated launch of a new hearing aid in the summer of 2025, which is expected to be a key catalyst for growth acceleration in the fourth quarter of 2025 and into 2026. Further bolstering this positive view are Demant's strategic shifts, including a revised managed care strategy and enhanced pricing flexibility with large accounts, which analysts interpret as signs of pragmatic management adept at addressing previous challenges. Despite acknowledging recent estimate cuts, Kepler Cheuvreux believes these positive catalysts will more than offset any negatives for Demant in 2025. Notably, Demant's stock is reported to be trading at a mid-teens discount to its historical average price-to-earnings ratio, suggesting a potential for re-rating as the company's growth trajectory improves.

Key Decisions for Investors

• Investors may consider the upgraded Buy rating and increased DKK315 price target as a signal of potential upside, underpinned by specific growth catalysts.
• Monitor Demant's progress towards the 2025 new product launch and the tangible impacts of its strategic adjustments in managed care and pricing, as these are crucial for realizing the projected growth.
• Given the stock's valuation discount relative to its historical P/E, assess whether the anticipated growth acceleration and strategic execution can bridge this gap and lead to a re-rating.